Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.79 |
| ▸ | JAK1 | P23458 | 10/20 | 0.79 |
| ▸ | JAK3 | P52333 | 18/20 | 0.71 |
| ▸ | TYK2 | P29597 | 4/20 | 0.71 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.67 |
| ▸ | MARK3 | P27448 | 2/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.67 |
| ▸ | STK3 | Q13188 | 2/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.67 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.67 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.67 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.67 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.67 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.67 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316849 | 1.00 | JAK2 (0.79) | JAK2JAK1JAK3TYK2PKN2 | |
| SCHEMBL7494320 | 0.94 | JAK2 (0.71) | JAK2JAK1JAK3TYK2PKN2 | |
| SCHEMBL4064069 | 0.88 | JAK3 (0.73) | JAK2JAK1JAK3TYK2PKN2 | |
| SCHEMBL28416005 | 0.88 | JAK1 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL20183293 | 0.88 | JAK1 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL3674893 | 0.88 | JAK3 (0.79) | JAK2JAK1JAK3TYK2PKN2 | |
| SCHEMBL3051157 | 0.88 | JAK3 (0.79) | JAK2JAK1JAK3TYK2PKN2 | |
| SCHEMBL4069943 | 0.88 | JAK3 (0.71) | JAK2JAK1JAK3TYK2PKN2 | |
| SCHEMBL4063458 | 0.87 | JAK3 (0.70) | JAK2JAK1JAK3TYK2PKN2 | |
| SCHEMBL4065801 | 0.87 | JAK3 (0.70) | JAK2JAK1JAK3TYK2PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265221-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER, INC. (US) | 2007-09-04 | — | — | US | claimed |
| US-7842699-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-RE41783-E1 | Immunosuppressants; organ transplant; CP 690550 which is 3-(4-Methyl-3-(methyl-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-amino)-piperidin-1-yl)-3-oxo-propionitrile; inhibitors of the enzyme protein kinases such as Janus Kinase 3 | PFIZER INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100035903-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | BLUMENKOPF TODD A | 2010-02-11 | — | — | US | disclosed |
| EP-1382339-B1 | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives | PFIZER PROD INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7265221-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7250420-B2 | Method of treatment of transplant rejection | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060241131-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2006-10-26 | — | — | US | disclosed |
| US-7091208-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050288313-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| US-6956041-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050113395-A1 | Method of treatment of atherosclerosis | PFIZER INC | 2005-05-26 | — | — | US | disclosed |
| CN-1195755-C | Pyrrolo [2,3-d] pyrimidine compounds | PFIZER PROD INC (US) | 2005-04-06 | — | — | CN | disclosed |
| US-20040116449-A1 | Method of treatment of transplant rejection | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20040053947-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1382339-A1 | Compositions containing pyrrolo [2,3-d] pyrimidine derivatives | Pfizer Products Inc. (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1235830-B1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS | PFIZER PROD INC (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6627754-B2 | Immunosuppressants; organ transplant; CP 690550 which is 3-(4-Methyl-3-(methyl-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-amino)-piperidin-1-yl)-3-oxo-propionitrile | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| CN-1409712-A | Pyrrolo [2, 3-d ] pyrimidine compounds | PFIZER PROD INC (US) | 2003-04-09 | — | — | CN | disclosed |
| US-20010053782-A1 | Immunosuppressants; organ transplant | BLUMENKOPF TODD A (US) | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035903-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | JAK3, JAK1, PDXK | JAK2 5/4885JAK1 2/4885JAK3 1/4885 |
| US-20040053947-A1 | Pyrrolo[2,3-D]pyrimidine compounds | JAK1, JAK3, TPMT | JAK2 8/4885JAK1 1/4885JAK3 2/4885 |
| US-20050288313-A1 | Pyrrolo[2,3-D]pyrimidine compounds | JAK3, JAK1, PDXK | JAK2 5/4885JAK1 2/4885JAK3 1/4885 |
| US-20060241131-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, PDXK | JAK2 5/4885JAK1 2/4885JAK3 1/4885 |
| US-20010053782-A1 | Immunosuppressants; organ transplant | JAK1, JAK3, TPMT | JAK2 14/4885JAK1 1/4885JAK3 2/4885 |
| US-20050113395-A1 | Method of treatment of atherosclerosis | LDLR, MSR1, NR1H2 | JAK2 1703/4885JAK1 3055/4885JAK3 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.